Chongqing Bowei Baitai Biopharmaceutical

Chongqing Bowei Baitai Biopharmaceutical is a Chinese biotechnology company specializing in the research, development, and industrialization of recombinant protein vaccines. As a major subsidiary of Chongqing Bowei Biopharmaceutical, the company focuses on high-value prophylactic vaccines, particularly multi-valent Human Papillomavirus (HPV) vaccines. Its advanced pipeline includes 2-valent, 4-valent, and 9-valent HPV vaccines in Phase 3 clinical trials, as well as a world-first 15-valent HPV vaccine candidate. The company operates a large-scale manufacturing base in the Chongqing International Biological City designed to meet international GMP standards. Bowei Baitai aims to address significant unmet needs in infectious disease prevention and oncology through its proprietary protein expression and purification platforms.